BioMarins Gene Therapy for Hemophilia A Continues to Impress – Rare Disease Report (blog)
Rare Disease Report (blog) |
BioMarins Gene Therapy for Hemophilia A Continues to Impress
Rare Disease Report (blog) FDA has granted Breakthrough Therapy Designation to Biomarin's gene therapy for hemophilia A, valoctocogene roxaparvovec (BMN 270). BioMarin Announces Third Quarter 2017 Financial Results |
